-+ 0.00%
-+ 0.00%
-+ 0.00%

Moderna Highlights Clinical Findings Supporting FDA Approval Of 2025-2026 Spikevax Formula Targeting LP.8.1 COVID-19 Variant

Benzinga·09/16/2025 10:13:24
Listen to the news
  • Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups
  • Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula of Spikevax